Immunocore takes ImmTAAI platform into type 1 diabetes with first patient dosed

The UK biotech has begun its first tissue-specific autoimmune trial, testing whether IMC-S118AI can protect insulin-producing beta cells while it expands beyond its KIMMTRAK-led cancer business. Immunocore said on 15 October, 2026, that it had dosed the first patient in…















